Share on StockTwits

Zogenix (NASDAQ:ZGNX) Director Cam L. Garner acquired 30,000 shares of the stock on the open market in a transaction dated Friday, June 13th. The stock was purchased at an average price of $1.66 per share, with a total value of $49,800.00. Following the completion of the transaction, the director now directly owns 326,750 shares in the company, valued at approximately $542,405. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at R. F. Lafferty initiated coverage on shares of Zogenix in a research note on Friday, June 6th. They set a “buy” rating and a $3.50 price target on the stock. They noted that the move was a valuation call. Separately, analysts at William Blair reiterated an “outperform” rating on shares of Zogenix in a research note on Monday, May 12th. They now have a $5.00 price target on the stock, down previously from $6.00. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Zogenix in a research note on Friday, April 25th. They now have a $5.00 price target on the stock.

Shares of Zogenix (NASDAQ:ZGNX) opened at 1.78 on Wednesday. Zogenix has a one year low of $1.47 and a one year high of $5.19. The stock has a 50-day moving average of $2.10 and a 200-day moving average of $3.23. The company’s market cap is $248.4 million.

Zogenix (NASDAQ:ZGNX) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.03. The company had revenue of $7.70 million for the quarter, compared to the consensus estimate of $8.71 million. During the same quarter in the prior year, the company posted ($0.17) earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. On average, analysts predict that Zogenix will post $-0.64 earnings per share for the current fiscal year.

Zogenix, Inc (NASDAQ:ZGNX) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.